
    
      The patients will receive infusion of ThisCART22 cells from health donor ,to evaluate the
      safety and efficacy of ThisCART22 Cells in patients with refractory or relapsed CD22-positive
      B cell malignancies.

      In this study, the dose range is 0.2-60 x10^6 cells per kg body weight (no more than 3.0 x
      10^9 in total).
    
  